Nick Roelofs brings over 40 years of international leadership experience in the life science tools and diagnostics industry, combining deep scientific expertise with a proven track record of scaling businesses and commercialising advanced technologies. With two PhDs and deep expertise in chemistry, he has held senior executive positions at Agilent Technologies, Bio-Rad Laboratories and Stratagene. As President of Agilent’s Life Sciences Group, he led a global business generating approximately US$3 billion in annual revenue and oversaw strategic acquisitions, including Dako, acquired for US$2.2 billion, Stratagene, Velocity 11, and Halo Genomics. Across his career, Nick has been involved in 23 acquisitions, 4 divestments and 12 exits through executive, advisory and board roles.
Nick has extensive experience in strategic investments, corporate acquisitions and board-level leadership across public and private life science companies. His board appointments include Olink and The Binding Site, both subsequently acquired by Thermo Fisher Scientific in multibillion-dollar transactions, as well as LGC Group and Seer, where he serves as Lead Independent Director. He also serves as an adviser to Nordic Capital and has previously served as a Thematic Partner at Summa Equity.
Alongside his commercial achievements, Nick has contributed to innovation in molecular diagnostics. At Applied Biosystems, Stratagene, and Bio-Rad he played a role contributing to the development and/or commercialisation of over 100 PCR technologies or products. He has also been directly involved in technologies around nucleic acid synthesis, single cell detection, antibody production and Next Generation Sequencing.
At Sciety, Nick draws on his scientific, commercial and investment expertise to evaluate investment opportunities and support portfolio companies in their growth. His active involvement includes board positions at Sciety portfolio companies PeptiSystems and Capitainer, where he contributes strategic insight and experience in scaling technology-driven businesses.